Iryna Drozd Larimar Therapeutics ( NASDAQ: LRMR ) stock shot up 24% in after hours trading Monday on news the FDA had removed a partial clinical hold on Larimar's nomlabofusp clinical program following a review of Phase 2 data for the drug. Larimar has been testing the drug for the treatment of Friedreich's ataxia, or FA. Interim data from an open label extension study is expected in Q4 , with submission of an FDA market application targeted for the second half of 2025.
Other companies developing treatments for FA include PTC Therapeutics ( PTCT ) and Design Therapeutics ( DSGN ). Biogen ( BIIB ) received EU approval for its FA drug Skyclarys in February; the drug is already on the market in the US. More on Larimar Therapeutics Seeking Alpha’s Quant Rating on Larimar Therapeutics Historical earnings data for Larimar Therapeutics Financial information for Larimar Therapeutics.
